IMVT - Immunovant, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
IMVT price evolution
IMVT
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $690.94 | $269.93 | $329.96 | $376.53 |
| Short term investments | ||||
| Net receivables | $1.03 | $1.42 | $0.82 | $0.7 |
| Inventory | ||||
| Total current assets | $710.78 | $291.18 | $350.01 | $404.33 |
| Long term investments | ||||
| Property, plant & equipment | $0.67 | $0.89 | $1.21 | $1.5 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.67 | $0.89 | $1.21 | $1.5 |
| Total investments | ||||
| Total assets | $711.45 | $292.07 | $351.22 | $405.84 |
| Current liabilities | ||||
| Accounts payable | $3.91 | $7.51 | $26.46 | $1.7 |
| Deferred revenue | ||||
| Short long term debt | $0.31 | $0.61 | $0.92 | $1.17 |
| Total current liabilities | $32.1 | $40.26 | $51.36 | $43.3 |
| Long term debt | $0.05 | |||
| Total noncurrent liabilities | $0.05 | |||
| Total debt | $0.31 | $0.61 | $0.92 | $1.22 |
| Total liabilities | $32.1 | $40.26 | $51.36 | $43.34 |
| Shareholders' equity | ||||
| Retained earnings | -$750.36 | -$698.95 | -$640.28 | -$566.35 |
| Other shareholder equity | -$0.6 | $0.51 | $0.58 | $0.85 |
| Total shareholder equity | $679.34 | $251.81 | $299.87 | $362.49 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $376.53 | $493.82 | $400.15 | $100.57 |
| Short term investments | ||||
| Net receivables | $0.7 | $12.23 | $12.86 | $0.5 |
| Inventory | ||||
| Total current assets | $404.33 | $512.93 | $409.01 | $109.08 |
| Long term investments | ||||
| Property, plant & equipment | $1.5 | $2.63 | $3.48 | $0.07 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.5 | $2.63 | $3.48 | $0.31 |
| Total investments | ||||
| Total assets | $405.84 | $515.56 | $412.49 | $109.39 |
| Current liabilities | ||||
| Accounts payable | $1.7 | $18.8 | $2.43 | $4.38 |
| Deferred revenue | ||||
| Short long term debt | $1.17 | $1.15 | $1.18 | |
| Total current liabilities | $43.3 | $44.52 | $18.77 | $15.32 |
| Long term debt | $0.05 | $1.22 | $2.24 | |
| Total noncurrent liabilities | $0.05 | $1.22 | $2.24 | |
| Total debt | $1.22 | $2.36 | $3.42 | |
| Total liabilities | $43.34 | $45.74 | $21.01 | $15.32 |
| Shareholders' equity | ||||
| Retained earnings | -$566.35 | -$355.39 | -$198.66 | -$91.23 |
| Other shareholder equity | $0.85 | $0.4 | -$0.3 | -$0.02 |
| Total shareholder equity | $362.49 | $469.82 | $391.48 | $94.07 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $48.34 | $47.96 | $50.58 | $51.84 |
| Selling, general & administrative | $13.21 | $13.84 | $15.4 | $12.42 |
| Total operating expenses | $61.55 | $61.8 | $78.48 | $63.9 |
| Operating income | -$61.55 | -$61.8 | -$78.48 | -$63.9 |
| Income from continuing operations | ||||
| EBIT | -$51.53 | -$58.21 | -$73.95 | -$60.42 |
| Income tax expense | -$0.11 | $0.45 | -$0.01 | -$0.99 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$51.42 | -$58.66 | -$73.94 | -$59.43 |
| Income (for common shares) | -$51.42 | -$58.66 | -$73.94 | -$59.43 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $160.26 | $101.81 | $68.6 | $47.93 |
| Selling, general & administrative | $48.02 | $54.23 | $39.51 | $18.15 |
| Total operating expenses | $218.53 | $156.03 | $108.12 | $66.08 |
| Operating income | -$218.53 | -$156.03 | -$108.12 | -$66.08 |
| Income from continuing operations | ||||
| EBIT | -$210.95 | -$156.81 | -$107.79 | -$65.67 |
| Income tax expense | $0.01 | -$0.08 | -$0.36 | $0.1 |
| Interest expense | $0.63 | |||
| Net income | ||||
| Net income | -$210.96 | -$156.73 | -$107.43 | -$66.39 |
| Income (for common shares) | -$210.96 | -$156.73 | -$107.43 | -$66.39 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$51.42 | -$58.66 | -$73.94 | -$59.43 |
| Operating activities | ||||
| Depreciation | $0.35 | $0.35 | $0.34 | $0.34 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.22 | $10.53 | $10.69 | $7.55 |
| Total cash flows from operations | -$47.1 | -$60.06 | -$47.37 | -$55.79 |
| Investing activities | ||||
| Capital expenditures | -$0.13 | -$0.03 | -$0.04 | -$0.03 |
| Investments | ||||
| Total cash flows from investing | -$0.13 | -$0.03 | -$0.04 | -$0.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $475.86 | $0.15 | $0.89 | $0.23 |
| Net borrowings | ||||
| Total cash flows from financing | $469.84 | $0.15 | $0.89 | $0.23 |
| Effect of exchange rate | -$1.61 | -$0.09 | -$0.05 | -$0.49 |
| Change in cash and equivalents | $421.01 | -$60.03 | -$46.57 | -$56.08 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$210.96 | -$156.73 | -$107.43 | -$66.39 |
| Operating activities | ||||
| Depreciation | $1.32 | $1.23 | $1 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $32.3 | $34.24 | $18.82 | $6.96 |
| Total cash flows from operations | -$188.19 | -$106.11 | -$83.33 | -$53.36 |
| Investing activities | ||||
| Capital expenditures | -$0.2 | -$0.25 | -$0.21 | -$0.03 |
| Investments | ||||
| Total cash flows from investing | -$0.2 | -$0.25 | -$0.21 | -$0.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $71.16 | $0.13 | $387.54 | $1.16 |
| Net borrowings | -$3.19 | $37.91 | ||
| Total cash flows from financing | $70.89 | $200.13 | $383.11 | $146.97 |
| Effect of exchange rate | $0.22 | -$0.09 | ||
| Change in cash and equivalents | -$117.28 | $93.67 | $299.57 | $93.59 |
News
Fundamentals
| Market cap | $4.26B |
|---|---|
| Enterprise value | $3.57B |
| Shares outstanding | 145.09M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$242.72M |
| EBIT | -$244.10M |
| Net Income | -$243.45M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -17.52 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -14.72 |
| EV/EBIT | -14.64 |
| P/S ratio | N/A |
| P/B ratio | 6.27 |
| Book/Share | 4.69 |
| Cash/Share | 4.76 |
| EPS | -$1.68 |
|---|---|
| ROA | -55.31% |
| ROE | -61.11% |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | 2.71 |
| Current ratio | 22.14 |
| Quick ratio | 22.14 |